Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Filipits, M; Rudas, M; Singer, CF; Fitzal, F; Bago-Horvath, Z; Greil, R; Balic, M; Lax, SF; Halper, S; Hulla, W; Wu, NC; Liu, X; Weidler, J; Bates, M; Hlauschek, D; Gnant, M; Dubsky, P.
ESR1, PGR, ERBB2, and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: results from ABCSG Trial 6.
ESMO Open. 2021; 6(4): 100228 Doi: 10.1016/j.esmoop.2021.100228 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Co-authors Med Uni Graz
Balic Marija

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

BACKGROUND: The purpose of this study was to assess the concordance of real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR) detection of ESR1, PGR, ERBB2, and MKi67 messenger RNA (mRNA) in breast cancer tissues with central immunohistochemistry (IHC) in women treated within the prospective, randomized Austrian Breast and Colorectal Cancer Study Group (ABCSG) Trial 6. PATIENTS AND METHODS: We evaluated ESR1, PGR, ERBB2, and MKi67 mRNA expression by Xpert® Breast Cancer STRAT4 (enables cartridge-based RT-qPCR detection of mRNA in formalin-fixed paraffin-embedded tissues) and estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 protein expression by IHC [in situ hybridization (ISH) for HER2 IHC 2+] in 1115 surgical formalin-fixed paraffin-embedded specimens from patients of ABCSG Trial 6. Overall percent agreement (concordance), positive percent agreement (sensitivity), and negative percent agreement (specificity) between STRAT4 and IHC were determined for each marker. The primary objective of the study was concordance between STRAT4 mRNA measurements of ESR1, PGR, ERBB2, and MKi67 with central reference laboratory IHC (and ISH for HER2 IHC 2+ cases). Time to distant recurrence was analyzed by Cox models. RESULTS: All performance targets for ER, PR, and Ki67 were met. For HER2, the negative percent agreement target but not the positive percent agreement target was met. Concordance between STRAT4 and IHC was 98.9% for ER, 89.9% for PR, 98.2% for HER2, and 84.8% for Ki67 (excluding intermediate IHC 10%-20% staining). In univariable and multivariable Cox regression analyses, all four biomarkers tested by either STRAT4 RT-qPCR or by central IHC (ISH) had a comparable time to distant recurrence indicating similar prognostic value. CONCLUSIONS: With the exception of HER2, we demonstrate high concordance between centrally assessed IHC and mRNA measurements of ER, PR, and Ki67 as well as a high correlation of the two methods with clinical outcome. Thus, mRNA-based assessment by STRAT4 is a promising new tool for diagnostic and therapeutic decisions in breast cancer.
Find related publications in this database (using NLM MeSH Indexing)
Biomarkers, Tumor - genetics
Breast Neoplasms - diagnosis, genetics
Estrogen Receptor alpha - genetics
Female - administration & dosage
Hormones - administration & dosage
Humans - administration & dosage
Ki-67 Antigen - genetics
Neoplasm Recurrence, Local - administration & dosage
Postmenopause - administration & dosage
Prospective Studies - administration & dosage
RNA, Messenger - genetics
Receptor, ErbB-2 - administration & dosage
Receptors, Progesterone - genetics

Find related publications in this database (Keywords)
early breast cancer
postmenopausal women
© Med Uni GrazImprint